TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00122616

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alpha-2a (Pegasys®)
Description: Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HIV antiretroviral therapy
Description: All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HIV antiretroviral therapy
Description: All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
Study: NCT01946633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic-controlled capsule endoscopy(Navicam)
Study: NCT01674946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: intraduodenal perfusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intraduodenal perfusion
Study: NCT01277822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan (+) amlodipine
Description: One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match losartan/amlodipine tablets
Description: One tablet containing placebo, orally, once daily, for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine camsylate
Description: 2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match amlodipine
Description: 2 tablets containing placebo, orally, once daily, for 8 weeks.
Study: NCT01901614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LALAK
Description: 1. A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~2. The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IEK
Description: 1. A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~2. In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Retrobulbar Block or General Anesthesia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography (OCT)
Description: OCT will be used to guide the depth of the graft and donor dissections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Anesthesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femtosecond laser
Description: The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femtosecond laser
Description: The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
Study: NCT04449107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Android based mobile phone application
Description: An android based mobile application will be developed. The application will have features and capacity for text messages, voice messages, pictorial messages and video messages. The content of the messages will be according to the findings of Paigham e sehat project and the four messages domains would be educational, reminder, religious and adverse effects. In addition, pictorial and video messages would be used as per freely available through EPI programme Pakistan.
Study: NCT03619434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser
Description: The laser will be used to make incisions in the cornea for the graft.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trephine blade
Description: A trephine blade will be used to make incisions in the cornea for the graft
Study: NCT01299467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active (PF-03526299)
Description: Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active (PF-03526299)
Description: Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active (PF-03526299)
Description: Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
Study: NCT01674946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bile acid (CDCA, chenodeoxycholic acid)
Description: intraduodenal perfusion
Study: NCT01299467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active (PF-03526299)
Description: Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
Study: NCT02478814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Amino acid intakes will be varied at 0.2-2.6 g/kg/day
Study: NCT01843166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Premarin vaginal cream
Description: 2g at bedtime twice weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: 2g at bedtime twice weekly
Study: NCT01836536

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab standard of care
Description: Standard treatment associated with circulating leucocytes (blood samplings)
Study: NCT03081663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quads-Sparing Approach
Description: Quadriceps-sparing mid-vastus approach for total knee arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quads-Sparing Approach
Description: Quadriceps-sparing mid-vastus approach for total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Para-Patellar Approach
Description: Medial para-patellar approach for total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medial Para-Patellar Approach
Description: Medial para-patellar approach for total knee arthroplasty
Study: NCT05151159

Intervention type: OTHER
Intervention: immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3

Intervention type: OTHER
Intervention: immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3

Intervention type: OTHER
Intervention: immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3

Intervention type: OTHER
Intervention: immunohistochemical analysis with murine monoclonal antihuman antibodies IMP3
Study: NCT01864148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033
Study: NCT01864148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avonex
Study: NCT04670263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tear Film Imager
Description: Tear Film Imager recording

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tear Film Imager
Description: Tear Film Imager recording
Study: NCT01220401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exposure, relaxation, and rescription therapy
Description: veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
Study: NCT02702609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: easy-graft CLASSIC
Description: easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA with collagen plug
Description: FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
Study: NCT02997865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped care for depression
Description: Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
Study: NCT01060748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE527
Description: ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03130907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of ureteral stent
Description: will randomize groups to either receive a postoperative ureteral stent or not.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of ureteral stent
Description: will randomize groups to either receive a postoperative ureteral stent or not.
Study: NCT02295228

Intervention type: OTHER
Intervention: No intervention
Description: There are no interventions. This is an observational trial.
Study: NCT05879393

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OMNi-BiOTiC® Active
Description: Multistrain probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: rice starch, maltodextrin, plant protein, potassium chloride, magnesium sulphate, manganese sulphate
Study: NCT03936907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OWCP Orally Disintegrating Tablet
Description: Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: Sativex® Oromucosal Spray
Study: NCT04405999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride
Description: Medical personnel at risk for COVID-19 infection will receive study medication for 14 days
Study: NCT04231682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Injection
Description: Use of denosumab in post liver transplant patient for prevention and management of osteoporosis and bone loss.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
Study: NCT01674946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bile acid (CDCA, chenodeoxycholic acid)
Description: intraduodenal perfusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oleanolic acid
Description: intraduodenal perfusion

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oleic acid
Description: intraduodenal perfusion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oleic acid
Description: intraduodenal perfusion
Study: NCT03063398

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention, this is an observational study
Description: Assessment for exocrine pancreatic insufficiency
Study: NCT00517816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1671
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1671
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1671
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1671
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1671
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1671
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)
Study: NCT04993521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block type
Description: Regular block type

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block type
Description: Regular block type
Study: NCT00635167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced-Transrectal Ultrasound
Description: Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline \[Visit 2\]); week 5 (middle of treatment \[Visit 3\]); week 10 (end of treatment \[Visit 4\]); week 18 (2 months after end of EBRT \[Visit 5\]); week 26 (4 months after end of EBRT \[Visit 6\]); and week 36 (6 months after end of EBRT \[Visit 7\]).
Study: NCT04779060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal fentanyle
Description: 25 mic fentanyle added to heavy bupivacaine for spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 8 mg dexamethasone give intrathecally for spinal anaesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: normal saline will be mixed with bupivacaine intrathecally
Study: NCT02619552

Intervention type: DRUG
Intervention: Anti-TNF
Description: All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.

Intervention type: DRUG
Intervention: Anti-TNF
Description: All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.

Intervention type: DRUG
Intervention: Steroids
Description: All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
Study: NCT01915017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Psychosis
Description: The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training
Description: CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-modal Cognitive Therapy
Description: A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Standard medication follow up and limited case management
Study: NCT02592668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Stimulator
Description: Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
Study: NCT01883804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyldopa
Description: 6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
Study: NCT01441518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home care
Description: Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital care
Description: Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists.
Study: NCT03693404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine, Duramorph , ketorolac
Description: Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine (Marcaine)
Description: 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthetics
Description: Placebo group will only receive standard of care general anesthesia
Study: NCT00638755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Description: Nasal Carbon Dioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Description: Nasal Carbon Dioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Description: Nasal Carbon Dioxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Description: Nasal Carbon Dioxide
Study: NCT00251589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 200 mg twice a day for 3 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg once a day for 3 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg twice a day for 3 days a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 400 mg once a day for 21 out of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150 mg once a day.